For more than twelve years, POZEN has been committed to developing products that offer innovative solutions to the unmet needs of patients, including product candidates for the treatment of migraine and arthritis.  In addition to our focus on the treatment of pain and painful conditions, POZEN is differentiated from other small pharmaceutical companies by a unique business model, singular innovation, and exceptional employees who are driven to succeed.

POZEN pioneered the concept of an outsource drug development company whose products would be marketed by strong commercial partners.  This model allows us to commit our resources to developing new products instead of funding laboratories, manufacturing facilities, or commercial infrastructure.  By licensing our products to market leaders, as we’ve done with Treximet™ and PN 400, we’ve capitalized on the large pharmaceutical companies’ strong relationships with patients, prescribers and third party payers. 

Although one would hope a small company could successfully streamline its products to full commercial status, I am certain the model we have chosen to follow better positions our products to reach their full commercial potential.  Instead of commercializing our innovative products ourselves, we take a royalty on net sales.  As a result cash begins to flow immediately after the product is launched by our partner and continues for years with no offsetting expense to POZEN.

The key to POZEN’s success is innovation.  Combining two different pharmacologic agents to provide a superior outcome for migraine patients may seem obvious today.  However, this exquisite solution to the migraine problem was never suggested until we developed it and convinced the skeptics through significant clinical trials.  Today, almost anyone you ask will say that dual acting migraine therapy is a “no brainer”, but this simply was not the case 11 years ago.  It reminds me of the famous saying, “The unfortunate thing about being ahead of your time is that when people finally realize you were right, they’ll say it was obvious all along.”    

The key to execution is a solid team.   The people who work at POZEN are selected for their ability to adhere to high standards of performance, their integrity, and their goal-oriented behavior.  No matter how good the plan, one can expect the unexpected in any drug development program.  POZEN employees have continuously demonstrated their ability to meet drug development challenges every step of the way.  There is no finer example of this than our successful navigation of the difficult path to the Treximet approval by the FDA.

We believe Treximet’s approval and launch by GlaxoSmithKline will be a transformational event for POZEN.  We are one of only a handful of small pharma companies to secure FDA approval for one of our inventions.  As we look forward to the submission and approval process for our other products, we are confident the advantages of our business model will become readily apparent to key players in our industry.  Not only will this realization enhance our reputation, but also our profitability when those products reach the marketplace.